The War Between the Land and the Sea is a five-part Doctor Who spin-off miniseries created by Russell T Davies. It premiered on BBC One and iPlayer, with episodes releasing weekly from December 7, ...
BBC One's hit sci-fi The War Between the Land and the Sea has wrapped up with an exciting season finale. The episode titled "The End of the War" reminds us that wars are devastating, no matter which ...
The finale goes to the dogs, quite literally, when it opens with Homo Aqua luring pooches out of their houses into the sea. Like a canine Weapons, if you will. The fish people point out that if humans ...
Spoiler alert! The following post contains major details about the ending of “The Housemaid” (in theaters now). Stop reading now if you haven’t seen it and don’t want to know. In “The Housemaid,” ...
SPOILER ALERT: This article contains major spoilers for “Avatar: Fire and Ash,” now playing in theaters. Director James Cameron is back with biggest and longest “Avatar” movie yet, “Fire and Ash.” ...
The ending of ‘Avatar: Fire and Ash’ hints at sequels, with the villain’s story left unresolved and Kiri still uncovering her connection to Eywa. ByDani Di Placido, Senior Contributor. Forbes ...
Director Jafar Panahi has a great deal in common with his “ It Was Just an Accident ” ensemble of characters, fellow Iranian dissidents who, like himself, have suffered incarceration, intimidation, ...
When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...
Spoilers for Season 5 of "Emily in Paris" ahead. From Rome to Paris to Venice and back to the City of Light, Season 5 of "Emily in Paris" takes viewers on a whirlwind European adventure. The hit ...
Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...
Recursion Pharmaceuticals, Inc. (RXRX) recently received a notable upgrade from JP Morgan analyst Eric Joseph, who shifted his rating to “Overweight” on December 17, 2025. This upgrade comes as the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback